The Netherlands
NovioSense BV, a spin-out from Fraunhofer Gesellschaft and NovioTech BV, is a pioneering company based in The Netherlands focusing on Medical Devices. Founded in 2012, the company is developing a wireless platform technology for non-invasive monitoring of disease biomarkers.
Its flagship innovation, a non-invasive glucose sensor, stands out for its ability to continuously monitor glucose levels in tear fluid, providing a potential breakthrough in diabetes management by offering an alternative to traditional invasive methods.
The company last secured a Series D investment on 24 October 2016, with backing from prominent investors such as Fraunhofer Venture, NovioTech, and Topfonds Gelderland.
NovioSense BV holds promising potential within the medtech industry, tapping into the growing demand for user-friendly, non-invasive health monitoring solutions. Investors should note its solid foundation in innovative research and strategic partnerships from established parent organizations.
